T Helper 1 (Th1), Th2, and Th17 Responses to Leishmania major Lipophosphoglycan 3.
Leishmania major is the main causal agent of cutaneous leishmaniasis (CL) that remains a serious public health concern in many tropical and subtropical countries. A long-lasting protective vaccine against leishmaniasis remains as a medical unmet need. Lipophosphoglycan 3 (LPG3) is one of the class II LPG genes from HSP90 family involved in the host immune responses. The aim of the present study is to investigate the capability of recombinant LPG3 (rLPG3) to induce Th1, Th2, Th17 responses. The results showed that rLPG3 in moderate and high concentrations significantly induced expression of Th1 lineage-specific transcription factor (T-bet) and cytokine (IFN-γ)(P < 0.05). Moreover, the Th1-stimulating effect of rLPG3 was confirmed by significant induction of IFN-γ secretion from treated T cells (P < 0.01). However, no significant effect of rLPG3 on Th2 and Th17 lineage cells was observed even in high concentration. Our findings demonstrate that rLPG3 induces Th1, but not Th2 and Th17, lineage responses. Further studies are needed to investigate adjuvant properties of rLPG3 for leishmania therapy.
a Department of Medical Parasitology and Mycology , School of Medicine, Alborz University of Medical Sciences , Karaj , Iran.
Abolfazl
A
Miahipour
b Drug Applied Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.|c Immunology Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.|d Department of Immunology, Faculty of Medicine , Tabriz University of Medical Sciences , Tabriz , Iran.
Mostafa
M
Haji-Fatahaliha
e Department of Medical Parasitology and Mycology, School of Public Health , Tehran University of Medical Sciences , Tehran , Iran.|f Center for Research of Endemic Parasites of Iran (CREPI) , Tehran University of Medical Sciences , Tehran , Iran.
Hossein
H
Keshavarz
a Department of Medical Parasitology and Mycology , School of Medicine, Alborz University of Medical Sciences , Karaj , Iran.
Mohammad Javad
MJ
Gharavi
b Drug Applied Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.|c Immunology Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.|d Department of Immunology, Faculty of Medicine , Tabriz University of Medical Sciences , Tabriz , Iran.
Hamed
H
Mohamadi
b Drug Applied Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.|c Immunology Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.|d Department of Immunology, Faculty of Medicine , Tabriz University of Medical Sciences , Tabriz , Iran.
Zohre
Z
Babaloo
g Molecular Immunology and Vaccine Research Lab , Pasteur Institute of Iran , Tehran , Iran.
Sima
S
Rafati
a Department of Medical Parasitology and Mycology , School of Medicine, Alborz University of Medical Sciences , Karaj , Iran.
Vahid
V
Younesi
b Drug Applied Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.|c Immunology Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.|d Department of Immunology, Faculty of Medicine , Tabriz University of Medical Sciences , Tabriz , Iran.
Maryam
M
Hosseini
b Drug Applied Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.|c Immunology Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.|d Department of Immunology, Faculty of Medicine , Tabriz University of Medical Sciences , Tabriz , Iran.
Mehdi
M
Yousefi
D002478:Cells, Cultured; D006028:Glycosphingolipids / Q000276:immunology / Q000494:pharmacology*; D006801:Humans; D056747:Immunomodulation; D007371:Interferon-gamma / Q000378:metabolism; D018320:Leishmania major / Q000276:immunology*; D054332:Leishmaniasis Vaccines / Q000276:immunology*; D016773:Leishmaniasis, Cutaneous / Q000276:immunology / Q000517:prevention & control*; D015800:Protozoan Proteins / Q000276:immunology / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000276:immunology / Q000494:pharmacology; D020825:T-Box Domain Proteins / Q000235:genetics / Q000378:metabolism; D018417:Th1 Cells / Q000187:drug effects* / Q000276:immunology; D058408:Th1-Th2 Balance / Q000187:drug effects; D058504:Th17 Cells / Q000187:drug effects* / Q000276:immunology; D018418:Th2 Cells / Q000187:drug effects* / Q000276:immunology; D015854:Up-Regulation; D000098815:T-bet Transcription Factor
D006028:Glycosphingolipids; D054332:Leishmaniasis Vaccines; D015800:Protozoan Proteins; D011994:Recombinant Proteins; D020825:T-Box Domain Proteins; D000098815:T-bet Transcription Factor; C008290:lipophosphonoglycan; D007371:Interferon-gamma
IFN-γ; LPG3; T helper; T-bet; leishmaniasis